Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/6254
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- BA - IGM - Artigos de Periódicos [3736]
- IOC - Artigos de Periódicos [12840]
Metadata
Show full item record
HIV-1 POLYMORPHISM: A CHALLENGE FOR VACCINE DEVELOPMENT - A REVIEW
HIV-1/genética
HIV-1/imunologia
Polimorfismo Genético
Variação Genética
Desenho de Drogas
Humanos
Revisão
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil
Abstract
The perspective for the development of anti-HIV/AIDS vaccines became a target sought by several research groups and pharmaceutical companies. However, the complex virus biology in addition to a striking genetic variability and the limited understanding of the immunological correlates of protection have made this an enormous scientific challenge not overcome so far. In this review we presented an updating of HIV-1 subtypes and recombinant viruses circulating in South American countries, focusing mainly on Brazil, as one of the challenges for HIV vaccine development. Moreover, we discussed the importance of stimulating developing countries to participate in the process of vaccine evaluation, not only testing vaccines according to already defined protocols, but also working together with them, in order to take into consideration their local information on virus diversity and host genetic background relevant for the vaccine development and testing, as well as including local virus based reagents to evaluate the immunogenicity of the candidate vaccines.
DeCS
Vacinas contra AIDS/genéticaHIV-1/genética
HIV-1/imunologia
Polimorfismo Genético
Variação Genética
Desenho de Drogas
Humanos
Revisão
Share